BioCardia (BCDA) to Release Quarterly Earnings on Wednesday

BioCardia (NASDAQ:BCDA) will be releasing its earnings data after the market closes on Wednesday, March 27th. Analysts expect BioCardia to post earnings of ($0.11) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

BioCardia Price Performance

BCDA stock opened at $0.41 on Tuesday. BioCardia has a 1 year low of $0.36 and a 1 year high of $2.92. The stock’s fifty day moving average price is $0.45 and its 200-day moving average price is $0.50. The company has a market cap of $10.49 million, a P/E ratio of -0.65 and a beta of 1.50.

Insider Transactions at BioCardia

In related news, major shareholder Phillip Md Et Al Frost sold 129,802 shares of the company’s stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $0.43, for a total value of $55,814.86. Following the transaction, the insider now directly owns 1,896,025 shares in the company, valued at $815,290.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, major shareholder Phillip Md Et Al Frost sold 129,802 shares of the business’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $0.43, for a total transaction of $55,814.86. Following the completion of the sale, the insider now directly owns 1,896,025 shares of the company’s stock, valued at approximately $815,290.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Peter Altman acquired 108,108 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were acquired at an average cost of $0.46 per share, with a total value of $49,729.68. Following the transaction, the chief executive officer now owns 555,447 shares in the company, valued at $255,505.62. The disclosure for this purchase can be found here. Insiders own 23.90% of the company’s stock.

Hedge Funds Weigh In On BioCardia

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new position in shares of BioCardia in the first quarter worth approximately $28,000. Dimensional Fund Advisors LP purchased a new stake in shares of BioCardia during the first quarter valued at $57,000. Millennium Management LLC bought a new stake in BioCardia in the 2nd quarter worth approximately $42,000. BlackRock Inc. bought a new stake in BioCardia in the 2nd quarter worth approximately $88,000. Finally, Virtu Financial LLC purchased a new position in shares of BioCardia in the 4th quarter worth approximately $27,000. 20.57% of the stock is currently owned by institutional investors and hedge funds.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.